Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Drive Innovation in 30+ Therapeutics Toward Market Entry, Finds DelveInsight | Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceuti

DelveInsight's "Hereditary Angioedema - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies developing 30+ pipeline drugs in the Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Hereditary Angioedema treatment landscape. Learn more about the evolving pipeline Hereditary Angioedema @ https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

​Key Takeaways from the Hereditary Angioedema Pipeline Report

• In January 2026, BioCryst completed acquisition of Astria Therapeutics (completed January 25), expanding HAE portfolio with navenibart.
• In December 2025, Intellia dosed first patient in Phase 3 HAELO trial for NTLA-2002 gene editing therapy.
• The leading Hereditary Angioedema companies include Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others evaluating novel prophylactic and on‐demand agents to address unmet needs in attack prevention and rapid symptom resolution.
• Promising Hereditary Angioedema therapies include NTLA‐2002, Donidalorsen, STAR‐0215, Garadacimab, TAK‐743 300 mg, ADX‐324, CSL312, TAK‐667, Lanadelumab, KVD900, PHA121, BMN 331, and others spanning gene editing, antisense oligonucleotides, plasma kallikrein inhibitors, and Factor XIIa antagonists.
• DelveInsight's report segments approximately 30+ products by clinical stage into late‐stage (Phase III), mid‐stage (Phase II), early‐stage (Phase I), pre‐clinical, discovery, and inactive candidates, providing a roadmap for pipeline maturation and potential market entrants.

Download for Hereditary Angioedema updates @ https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Hereditary Angioedema Emerging Drugs Profile

• KVD900: KalVista Pharmaceuticals
KVD900 is an investigational oral plasma kallikrein inhibitor designed for on‐demand treatment of hereditary angioedema (HAE) attacks, offering rapid bradykinin pathway blockade to resolve symptoms without the need for injectable administration. In clinical studies, KVD900 has demonstrated fast absorption, potent kallikrein inhibition, and significant attack resolution within 2 hours, positioning it as a potential first oral on‐demand therapy for adults and adolescents with HAE. On September 17, 2025, KalVista initiated the KVD900‐303 open‐label multicenter trial in pediatric patients aged 2 to 11 years with HAE Type I/II, expanding its development to younger populations and supporting a broad label that could transform acute management.

• PHA121: Pharvaris
PHA121 is a potent, orally available plasma kallikrein inhibitor in Phase 2 development as an on‐demand therapy for acute HAE attacks, with a pharmacokinetic profile optimized for rapid onset and short duration to match attack kinetics. By inhibiting kallikrein to prevent bradykinin generation, PHA121 aims to provide effective symptom relief without injections, addressing patient preferences for convenience and accessibility in self‐treatment scenarios. As a mid‐stage asset highlighted by DelveInsight, PHA121 contributes to the growing portfolio of oral options that could disrupt the injectable‐dominant on‐demand market dominated by C1 inhibitors and bradykinin receptor antagonists.

For more information on the Hereditary Angioedema Emerging Drugs Profile, download DelveInsight's comprehensive Hereditary Angioedema Pipeline Insight report. @ https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

The Hereditary Angioedema Pipeline Report Provides

• Detailed insights about companies developing therapies for Hereditary Angioedema, with aggregate therapies developed by each company for the same.
• Different therapeutic candidates, segmented into early‐stage, mid‐stage, and late‐stage of development for Hereditary Angioedema treatment.
• Hereditary Angioedema companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hereditary Angioedema drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Hereditary Angioedema market.

Learn more about Hereditary Angioedema drugs opportunities in our comprehensive Hereditary Angioedema report @ https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Hereditary Angioedema Companies

There are 20+ key companies developing therapies for Hereditary Angioedema, such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others advancing gene therapies, oral prophylactics, and on‐demand treatments.

DelveInsight's Hereditary Angioedema pipeline report highlights that KalVista Pharmaceuticals and Pharvaris have lead assets in the most advanced Phase 3 and Phase 2 stages for oral on‐demand therapies, respectively.

DelveInsight's Hereditary Angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Hereditary Angioedema products have been categorized under various Molecule types such as:

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Discover the latest advancements in Hereditary Angioedema treatment by visiting our website. Stay informed about how we are transforming the future of disease @ https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Hereditary Angioedema Pipeline Report

• Coverage: Global
• Hereditary Angioedema companies: Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics and others
• Hereditary Angioedema Therapies: NTLA‐2002, Donidalorsen, STAR‐0215, Garadacimab, TAK‐743 300 mg, ADX‐324, CSL312, TAK‐667, Lanadelumab, KVD900 and others
• Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre‐clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare‐focused market research and consulting firm that provides clients with high‐quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.